Highlights of Ophthalmology

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Related articles

VOLUME 41 , ISSUE 6ENG ( Dec-2013, 2013 ) > List of Articles

REVIEW ARTICLE

Analysis of Two-year Corneal Cross-linking Results in Keratoconus Patients

Mohamed Iqbal Hafez

Citation Information : Hafez MI. Analysis of Two-year Corneal Cross-linking Results in Keratoconus Patients. 2013; 41 (6ENG):5-11.

DOI: 10.5005/hoo-10101-41602

Published Online: 25-03-2014

Copyright Statement:  Copyright © 2013; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

PURPOSE: To assess and analyze the two-year results of corneal collagen cross-linking with riboflavin using ultraviolet-A light in the treatment of keratoconus and to evaluate the efficacy of this procedure. DESIGN: Retrospective study. METHODS: The preoperative and postoperative data of 58 eyes of 40 keratoconus patients were revised. The intervention was only conventional corneal collagen cross linking in an indicated keratoconus patient. The data included UCVA, BCVA, slit lamp examination, keratometry, refractometry, pachymetry and corneal topography. Postoperative follow up program was 1, 3, 6, 12, 24 months. RESULTS: The mean age was 16.9 ± 6.35 years (range 12-39 years) and the mean follow-up was 23.05 ± 1.55 months (range 12 to 30 months). Fifty-eight eyes of 40 patients with a follow-up of at least 24 months were analyzed. The preoperative values on the day of treatment were compared with postoperative values of the 24-month examination. This showed that BCVA improved at least one line in 53.4% (31/58) of eyes, remained stable in 36.2 % (21/58) of eyes (P=0.006) and decreased by only one line in 10.3 % (6/58). Astigmatism remained stable (within ± 0.50 D) in 86.2% (50/58) of eyes while decrease by a mean of 1.20 D 13.8 % in (8/58) of eyes. The K value of the apex decreased by a mean of 2.73 D in 65.5% (38/58) of eyes (P=0.004), remained stable (within ± 0.50 D) in 25.9% (15/58) of eyes and increase by 1.00 D in 8.6 % (5/58) of eyes. The maximum K value decreased by a mean of 2.47D in 55.1% (32/58) of eyes (P=0.004), remained stable (within ± 0.50 D) in 38% (22/58) of eyes and increase by 1.00 D in 6.9 % (4/58) of eyes. Corneal wave front analysis revealed that spherical and higher-order aberrations did not show significant variations in the follow-up period. The coma component showed a very significant reduction at six months after treatment and persisted throughout the follow-up period (P=0.003). CONCLUSION: This study proved that corneal cross-linking is beneficial as both visual preserving and visual improving procedures. K readings are the main indicator of success or failure of the procedure. Central corneal thickness can be an indicator of improvement, there is a reciprocal relationship between them. Best chance is for patients with corneal thickness more than 400 ?m. It is advised that the crosslinkologist should store the riboflavin in the refrigerator from +4° C to +8° C and discard it immediately after surgery. Use of steroid from the first postoperative day was helpful. Most postoperative visual improvement resulted from decrease of myopia whereas there was no remarkable improvement of astigmatism.


PDF Share
  1. Rabinowitz YS. Keratoconus. Surv Ophthalmol 1998; 42:297-319.
  2. Caporossi A, Biaocchi S, Mazzota C, et al. Parasurgical therapy for keratoconus by riboflavin-ultraviolet type A rays induced cross-linking of corneal collagen: Preliminary refractive results in an Italian Study. J Cat Refract Surg 2006;32:837-45.
  3. Kymes SM, Walline JJ, Zadnik K, Gordon MO. Quality of life in keratoconus: The Collaborative Longitudinal Evaluation of Keratoconus (CLEK) Study Group. Am J Ophthalmol 2004;138:527-35.
  4. Kenney MC, Brown DJ, Rajeev B. Everett Kinsey lecture: The elusive causes of keratoconus: A working hypothesis. CLAO J 2000;26:10-3. [PubMed: 10656302]
  5. Polack F. Contribution of electron microscopy to the study of corneal pathology. Surv Ophthalmol 1976;20:375-414.
  6. Maurice DM. Some puzzles in the microscopic structure of the stroma. J Refract Surg 1996;12:677-83.
  7. Meek KM, Tuft SJ, Huang Y, et al. Changes in collagen orientation and distribution in keratoconus corneas. Invest Ophthalmol Vis Sci 2005;46:1948.
  8. Scott JE, Haigh M. Proteoglycan-type I collagen fibril interactions in bone and non-calcifying tissues. Biosci Rep 1985;5:71-81.
  9. Hirano K, Kobayashi M, Kobayashi K, et al. Experimental formation of 100 nm periodic fibrils in the mouse corneal stroma and trabecular meshwork. Invest Ophthalmol Vis Sci 1989;30:869-74.
  10. Rock ME, Moore MN, Anderson JA, et al. 3-D computer models of human keratocytes. CLAO J 1995;21:57-60.
  11. Yue BY, Baum JL, Smith BD. Identification of collagens synthesized by cultures of normal human corneal and keratoconus stromal cells. Biochem Biophys Acta. 1983;755:318-25.
  12. Smolek MK. Interlamellar cohesive strength in the vertical meridian of human eye bank corneas. Invest Ophthalmol Sci 1993;34:2962-9.
  13. Smolek MK, Beekhuis WH. Collagen fibril orientation in the human corneal stroma and its implications in keratoconus. Invest Ophthalmol Vis Sci 1997;38:1289-90.
  14. Wollensak G, Spoerl E, Seiler T. Riboflavin/ultraviolet-A-induced collagen cross-linking for the treatment of keratoconus. Am J Ophthalmol 2003;135:620-7.
  15. Wollensak G, Spoerl E, Wilsch M, Seiler T. Endothelial cell damage after riboflavin-ultraviolet: A treatment in the rabbit. J Cat Refract Surg 2003;29:1786-90.
  16. Wollensak G, Spoerl E, Seiler T. Stress-strain measurements of human and porcine corneas after riboflavin-ultraviolet-A-induced cross-linking. J Cat Refract Surg 2003;29:1780-5.
  17. Kohlhaas M, Spoerl E, Schilde T, et al. Biomechanical evidence of the distribution of cross-links in corneas treated with riboflavin and ultraviolet A light. J Cat Refract Surg 2006;32:279-83.
  18. Suzuki M, Amano S, Honda N, et al. Longitudinal changes in corneal irregular astigmatism and visual acuity in eyes with keratoconus. Jpn J Ophthalmol 2007;51:265-9.
  19. Raiskup-Wolf F, Hoyer A, Spoerl E, et al. Collagen cross-linking with riboflavin and ultraviolet-A light in keratoconus: Long-term results. J Cat Refract Surg 2008;34:796-801.
  20. Saini JS, Saroha V, Singh P, et al. Keratoconus in Asian eyes at a tertiary eye care facility. Clin Exp Optom 2004;87:97-101.
  21. Spoerl E, Mrochen M, Sliney D, et al. Safety of UVA-riboflavin cross-linking of the cornea. Cornea 2007;26:385-9.
  22. Andreassen TT, Simonsen AH, Oxlund H. Biomechanical properties of keratoconus and normal corneas. Exp Eye Res 1980;31:435-41.
  23. Wollensak G, Redl B. Gel eletrophoretic analysis of corneal collagen after photodynamic cross-linking treatment. Cornea 2008;27:353-6.
  24. Mazzotta C, Traversi C, Baiocchi S, et al. Corneal healing after riboflavin ultraviolet-A collagen cross-linking determined by confocal laser scanning microscopy in vivo: Early and late modification. Am J Ophthalmol 2008;146:527-53.
  25. Tuft SJ, Moodaley LC, Gregory WM, et al. Prognostic factors for the progression of keratoconus. Ophthalmology 1994;101:439-47.
  26. Kennedy RH, Bourne WM, Dyer JA. A 48-year clinical and epidemiologic study of keratoconus. Am J Ophthalmol 1986;101:267-73.
  27. Chan CC, Sharma M, Boxer Wachler BS. Effect of inferior segment Intacs with and without C3-R on keratoconus. J Cat Refract Surg 2007;33:75-80.
  28. Agrawal VB. Corneal collagen cross-linking with riboflavin and ultraviolet-A light for keratoconus: Results in Indian eyes. Indian J Ophthalmol 2009; 57(2): 111-4.
  29. Kasper M, Sporl E, Huhle M, et al. Erhohung der Festigkeit der Hornhaut durch vernetzung. [Artificial stiffening of the cornea by induction of intrastromal cross-links]. Ophthalmologe 1997;94:902-6.
  30. Kohlhaas M, Spoerl E, Schilde T, et al. Biomechanical evidence of the distribution of cross-links in corneas treated with riboflavin and ultraviolet A light. J Cat Refract Surg 2006;32:279-83.
  31. Sporl E, Huhle M, Seiler T. Induction of cross-links in corneal tissue. Exp Eye Res 1998;66:97-103.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.